Chronic Kidney Disease | FARXIGA® (dapagliflozin) 5 mg & 10 mg …
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100 (1):215-224.
A pre-specified analysis of the DAPA-CKD trial demonstrates ... - PubMed
Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to …
IgA Nephropathy Slows Kidney Function Loss with Dapagliflozin
Dapagliflozin tends to slow down chronic kidney disease and IgA nephropathy. Dapagliflozin is a generic drug for Farxiga, which recently was approved. The research shows that this medication helps slow …
A pre-specified analysis of the DAPA-CKD trial demonstrates the …
Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to …
Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
Jul 1, 2025 · Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pretreatment estimated glome…
New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
Apr 20, 2021 · Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the …
FDA Approves Sibeprenlimab for Patients with IgAN
Nov 26, 2025 · The FDA approved sibeprenlimab (Voyxact; Otsuka Pharmaceutical Co., Ltd, Visterra, Inc.), a monoclonal antibody targeting the cytokine A Proliferation-Inducing Ligand (APRIL), as a …
Sibeprenlimab: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
4 days ago · Sibeprenlimab is a prescription medication indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
Farxiga for Nephropathy - meds.is
Discover how Farxiga is used to treat IgA Nephropathy, a type of kidney disease, and its potential benefits for patients.
- Reviews: 341
Voyxact: FDA Grants Accelerated Approval to Once-Monthly ... - WebMD
Nov 26, 2025 · Voyxact (sibeprenlimab-szsi) is a new medicine approved by the FDA to lower protein levels in urine for adults with a kidney condition called primary immunoglobulin A nephropathy (IgAN) …